Radiotherapy Combined Immunotherapy

A special issue of Radiation (ISSN 2673-592X).

Deadline for manuscript submissions: 30 June 2024 | Viewed by 614

Special Issue Editors


E-Mail Website
Guest Editor
Department of Radiation Oncology, College of Medicine, Chungbuk National University, Chungdae-ro 1, Seowon-gu, Cheongju 28644, Republic of Korea
Interests: radiation resistance (X-ray, C-ion); EGFR signaling; notch signaling; epithelial mesenchymal transition (EMT); cancer stem cells (CSCs); cancer immunotherapy; radiation protection
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Biophysics Division, GSI Helmholtz Center for Heavy Ion Research, 64291 Darmstadt, Germany
Interests: space biology; radiobiology; cancer biology; tumor hypoxia; flash radiotherapy; cell and molecular biology; human pathology and physiology; hibernation and synthetic torpor; target therapies
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Radiotherapy (RT), a central module of cancer treatment, has the most appropriate nonsurgical modalities. This type of treatment is received by about half of all patients with cancer. RT is an influential treatment for both curative purposes, as well as for palliation and the maintenance of patients' quality of life. Recently, investigations have had several prime focuses regarding new technologies, such as FLASH RT, proton RT, and carbon ion RT, which aim to improve therapeutic efficacy in patients. The increasing evidence on the immunomodulatory effects of RT casts new light on the systemic antitumor response. This Special issue aims to deliver high-quality research with the goal of highlighting new treatment strategies, including X-rays, Proton therapy, and C-ion therapy, importantly, to target cancer stem cells and treat various cancers. We encourage contributors to submit manuscripts addressing any of the different aspects of radiation therapy and/or immunotherapy, including: radiation-combined immunotherapy; NK cells; new pharmacological drugs; radiation therapy, including X-rays, C-ions, Proton, and FLASH therapy; and basic and translational research.

Dr. D. S. Prabakaran
Dr. Walter Tinganelli
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Radiation is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer immunotherapy
  • NK cells
  • radiation

Published Papers

This special issue is now open for submission.
Back to TopTop